Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics
GET POWR RATINGS... FREE!
XERS POWR Grades
- Value is the dimension where XERS ranks best; there it ranks ahead of 61.69% of US stocks.
- XERS's strongest trending metric is Stability; it's been moving up over the last 163 days.
- XERS ranks lowest in Stability; there it ranks in the 4th percentile.
XERS Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for XERS is -14.36 -- better than merely 1.23% of US stocks.
- XERS's went public 3.59 years ago, making it older than just 11.24% of listed US stocks we're tracking.
- As for revenue growth, note that XERS's revenue has grown 134.09% over the past 12 months; that beats the revenue growth of 94.82% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Xeris Biopharma Holdings Inc, a group of peers worth examining would be INSG, TTOO, WINA, NLOK, and BNFT.
- XERS's SEC filings can be seen here. And to visit Xeris Biopharma Holdings Inc's official web site, go to www.xerispharma.com.
XERS Valuation Summary
- In comparison to the median Healthcare stock, XERS's price/earnings ratio is 106.03% lower, now standing at -2.2.
- XERS's price/earnings ratio has moved up 12.3 over the prior 39 months.
- Over the past 39 months, XERS's price/sales ratio has gone down 242.
Below are key valuation metrics over time for XERS.
XERS's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- XERS has a Quality Grade of D, ranking ahead of 9.9% of graded US stocks.
- XERS's asset turnover comes in at 0.208 -- ranking 192nd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows XERS's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
XERS Stock Price Chart Interactive Chart >
XERS Price/Volume Stats
|Current price||$2.10||52-week high||$7.94|
|Prev. close||$2.12||52-week low||$1.77|
|Day high||$2.12||Avg. volume||3,265,954|
|50-day MA||$2.31||Dividend yield||N/A|
|200-day MA||$2.86||Market Cap||139.64M|
Xeris Pharmaceuticals, Inc. (XERS) Company Bio
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Most Popular Stories View All
XERS Latest News Stream
|Loading, please wait...|
XERS Latest Social Stream
View Full XERS Social Stream
Latest XERS News From Around the Web
Below are the latest news stories about Xeris Biopharma Holdings Inc that investors may wish to consider to help them evaluate XERS as an investment opportunity.
Xeris Biopharma (NASDAQ:XERS) reaffirmed its 2021 pro forma net sales and year-end cash balance guidance. The company said preliminary 2021 full-year pro forma net sales at high-end of $76M-80M guidance, representing ~55% growth from 2020. Year-end 2021 preliminary cash, cash equivalents, and investments of ~$102M. The company said that more...
Mizuho Securities analyst Vamil Divan maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a price target of $8.00. The company's shares closed last Friday at $2.22, close to its 52-week low of $1.77. According to TipRanks.com, Divan has 0 stars on 0-5 stars ranking scale with an average return of -3.9% and a 44.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals. Xeris Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.85.
Xeris Biopharma Holdings Inc (NASDAQ: XERS ) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately 55% growth from 2020. The company held year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million. "2022 is off to a good Full story available on Benzinga.com
PANTHERx Rare has become the exclusive U.S. pharmacy distribution partner for Xeris Biopharma's (XERS +0.2%) recently approved medicine Recorlev (levoketoconazole) to treat Cushing's syndrome. Recorlev is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been...
PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome
PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole). Recorlev is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative. Cushing's syndrome, a disease assoc
XERS Price Returns
Continue Researching XERSWant to see what other sources are saying about Xeris Pharmaceuticals Inc's financials and stock price? Try the links below:
Xeris Pharmaceuticals Inc (XERS) Stock Price | Nasdaq
Xeris Pharmaceuticals Inc (XERS) Stock Quote, History and News - Yahoo Finance
Xeris Pharmaceuticals Inc (XERS) Stock Price and Basic Information | MarketWatch